Literature DB >> 24352455

Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

Andrew T McGuire1, Jolene A Glenn, Adriana Lippy, Leonidas Stamatatos.   

Abstract

UNLABELLED: Broadly neutralizing antibodies (bNAbs) against HIV-1 are generated during HIV-1-infection but have not yet been elicited by immunization with recombinant forms of the viral envelope glycoprotein (Env; the target of anti-HIV-1 neutralizing antibodies). A particular type of bNAb targets the CD4-binding site (CD4-BS) region of Env. These antibodies are derived from a limited number of VH/VL genes and can bind to and neutralize diverse HIV-1 strains. Recent reports have demonstrated the limited potential of Env to activate B cells expressing the germline B cell receptor (BCR) forms of anti-CD4-BS bNAbs. A potential reason for the lack of elicitation of anti-CD4-BS bNAbs by Env immunogens is the absence of stimulation of naive B cells expressing the germline BCRs of such antibodies. Several bNAbs have been isolated from HIV-1-infected subjects that target other structurally conserved regions of Env. How frequently Env immunogens stimulate the germline BCRs that give rise to bNAbs that target Env regions other than the CD4-BS is not well understood. Here, we investigated the interactions between diverse Envs and the BCRs of known bNAbs targeting not only the CD4-BS but also conserved elements of the second and third variable Env regions. Our results indicate that Env is generally ineffective in engaging germline BCRs of bNAbs irrespective of their epitope target. Potentially, this is the result of viral evolutionary mechanisms adopted to escape broadly neutralizing antibody responses. Our results also suggest that a single Env capable of activating germline BCRs that target distinct Env epitopes will be very difficult to identify or to design. IMPORTANCE: Broadly neutralizing antibodies against HIV-1 are thought to be an important component of the immune responses that a successful vaccine should elicit. Broadly neutralizing antibodies are generated by a subset of those infected by HIV-1, but so far, they have not been generated by immunization with recombinant Envelope (Env, the target of anti-HIV-1 neutralizing antibodies). Here, we provide evidence that the inability of Env to elicit the production of broadly neutralizing antibodies is due to the inability of diverse Envs to engage the germline B cell receptor forms of known broadly neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24352455      PMCID: PMC3958080          DOI: 10.1128/JVI.03228-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  77 in total

1.  Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Authors:  George Sellhorn; Zane Kraft; Zachary Caldwell; Katharine Ellingson; Christine Mineart; Michael S Seaman; David C Montefiori; Eliza Lagerquist; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

Review 2.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

3.  Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Authors:  Thaddeus M Davenport; Della Friend; Katharine Ellingson; Hengyu Xu; Zachary Caldwell; George Sellhorn; Zane Kraft; Roland K Strong; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

5.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Authors:  Katie J Doores; Michael Huber; Khoa M Le; Sheng-Kai Wang; Colleen Doyle-Cooper; Anthony Cooper; Ralph Pantophlet; Chi-Huey Wong; David Nemazee; Dennis R Burton
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

6.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

7.  Expression, purification, and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies.

Authors:  Naama Kessler; Anat Zvi; Min Ji; Michal Sharon; Osnat Rosen; Rina Levy; Miroslaw Gorny; Suzan Zolla-Pazner; Jacob Anglister
Journal:  Protein Expr Purif       Date:  2003-06       Impact factor: 1.650

8.  Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection.

Authors:  George Sellhorn; Zachary Caldwell; Christine Mineart; Leonidas Stamatatos
Journal:  Vaccine       Date:  2009-10-24       Impact factor: 3.641

9.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

10.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

View more
  48 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

2.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Authors:  Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley
Journal:  Virology       Date:  2017-03-06       Impact factor: 3.616

3.  Analysis of SIVmac Envelope-Specific Antibodies Selected Through Phage Display.

Authors:  Sergio Ita; Mayara R Agostinho; Katherine Sullivan; Seung Yub Han; Rana Akleh; Welkin E Johnson; Ismael Ben F Fofana
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

Review 4.  The Neutralizing Antibody Response to the HIV-1 Env Protein.

Authors:  Penny L Moore
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

5.  Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire.

Authors:  Cathrine Scheepers; Ram K Shrestha; Bronwen E Lambson; Katherine J L Jackson; Imogen A Wright; Dshanta Naicker; Mark Goosen; Leigh Berrie; Arshad Ismail; Nigel Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Penny L Moore; Simon A Travers; Lynn Morris
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

6.  Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.

Authors:  Syna Kuriakose Gift; Daniel P Leaman; Lei Zhang; Arthur S Kim; Michael B Zwick
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

Review 7.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

Review 8.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

9.  Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.

Authors:  Javier F Morales; Bin Yu; Gerardo Perez; Kathryn A Mesa; David L Alexander; Phillip W Berman
Journal:  Mol Immunol       Date:  2016-07-21       Impact factor: 4.407

10.  In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates.

Authors:  Grant C Weaver; Rina F Villar; Masaru Kanekiyo; Gary J Nabel; John R Mascola; Daniel Lingwood
Journal:  Nat Protoc       Date:  2016-01-07       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.